drugset / Trial / NCT07500298
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
Timeline
- Start
- 2026-05-20
- Primary completion
- 2030-12-27
- Completion
- 2032-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | SAR445877 | Unknown | — | Intravenous |